Literature DB >> 15542966

Other supportive therapies in sepsis: an evidence-based review.

Stephen Trzeciak1, R Phillip Dellinger.   

Abstract

OBJECTIVE: In 2003, critical care and infectious disease experts representing 11 international organizations developed management guidelines for other supportive therapies in sepsis that would be of practical use for the bedside clinician, under the auspices of the Surviving Sepsis Campaign, an international effort to increase awareness and improve outcome in severe sepsis.
DESIGN: The process included a modified Delphi method, a consensus conference, several subsequent smaller meetings of subgroups and key individuals, teleconferences, and electronic-based discussion among subgroups and among the entire committee.
METHODS: The modified Delphi methodology used for grading recommendations built on a 2001 publication sponsored by the International Sepsis Forum. We undertook a systematic review of the literature graded along five levels to create recommendation grades from A to E, with A being the highest grade. Pediatric considerations to contrast adult and pediatric management are in the article by Parker et al. on p. S591.
CONCLUSION: Patients with severe sepsis should be treated with deep-vein thrombosis prophylaxis. Low-dose unfractionated heparin or low molecular weight heparin is preferred. Use of graduated compression devices is recommended in septic patients with contraindication to the use of heparin or combined with heparin in very high-risk patients. Stress ulcer prophylaxis should be given to all patients with severe sepsis. Histamine-2 receptor antagonists are more effective than sucralfate in decreasing bleeding risk and transfusion requirements. Proton pump inhibitors have not been assessed in a direct comparison with histamine-2 receptor antagonists but do demonstrate equivalency and ability to increase gastric pH.

Entities:  

Mesh:

Year:  2004        PMID: 15542966     DOI: 10.1097/01.ccm.0000145915.53268.a8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

Review 1.  Recommendations for ulcer prophylaxis in the treatment of patients with severe sepsis and septic shock: a dog chasing its tail?

Authors:  Francesca Rubulotta; Antonino Gullo; Fulvio Iscra
Journal:  Intensive Care Med       Date:  2007-02-24       Impact factor: 17.440

2.  Low molecular weight heparin prevents lipopolysaccharide induced-hippocampus-dependent cognitive impairments in mice.

Authors:  Renqi Li; Jianhua Tong; Yuanhui Tan; Sihai Zhu; Jianjun Yang; Muhuo Ji
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.

Authors:  Stefan Jochberger; Viktoria Mayr; Günter Luckner; Dietmar R Fries; Andreas J Mayr; Barbara E Friesenecker; Ingo Lorenz; Walter R Hasibeder; Hanno Ulmer; Wolfgang Schobersberger; Martin W Dünser
Journal:  Crit Care       Date:  2005-08-09       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.